Search

Highlights from the SWG

SWG Session at EHA2023ELN-EHA SWG for CML: CML: modelling the futureChairJane Apperley (United Kingdom)

Topics and presenters
Identifying new targets for BCR::ABL1 inhibition: Oliver Hantschel (Germany). Dissecting phylogenetic trees in CML: Aleksandra Kamizela (United Kingdom).

Read more

Message from the EHA Board

After more than a decade of tireless work to further EHA’s mission our Executive Director, Carin Smand, has unfortunately announced that she will be leaving our organization.

Read more

Meet Eva Hellström-Lindberg, our Volunteer of the Month

Can you tell us what you do for EHA and when you started?
These days I am not as involved in EHA as I used to be, besides the various services when asked for, which I think is how it should…

Read more

Meet Eva Hellström-Lindberg, our Volunteer of the Month

Can you tell us what you do for EHA and when you started?
These days I am not as involved in EHA as I used to be, besides the various services when asked for, which I think is how it should…

Read more

A new form of inherited thrombocytopenia (ETV6-related thrombocytopenia, ETV6-RT): NEVER JUDGE A BOOK BY ITS COVER!

A new form of inherited thrombocytopenia (ETV6-related thrombocytopenia, ETV6-RT): NEVER JUDGE A BOOK BY ITS COVER!

We recently discovered a new form of an inherited deficiency of platelets (inherited thrombocytopenia-IT), which is caused by mutations in the ETV6-gene.

Read more

FDA Reports of Secondary Malignancies Following Chimeric Antigen Receptor (CAR) T Cell Therapies and Relative Risk: an EBMT-EHA-GoCART Coalition Statement

We need to bring your attention to the recent warning disseminated by the Food and Drug Administration (FDA) regarding T-cell lymphomas in patients undergoing Chimeric Antigen Receptor T-cell (CAR-T) therapy (1).

Read more

How to apply for an EHA Innovation Grant

On this page, we explain all of the actions you'll need to take when submitting an EHA Innovation Grant application.

Read more